6 citations
,
November 2022 in “BMC Urology” In this study, researchers found that the microRNA miR-1199-5p may reduce the expression of SRD5A2 in benign prostatic hyperplasia tissues, potentially contributing to the failure of 5-α reductase inhibitor therapy in some patients.
53 citations
,
June 1993 in “Proceedings of the National Academy of Sciences of the United States of America” This study identified LY191704 as a specific noncompetitive inhibitor of human 5 alpha-reductase type 1, which may be useful in treating endocrine disorders related to DHT overproduction.
8 citations
,
June 2017 in “Steroids” This study evaluated novel steroid compounds for their ability to inhibit 5α-reductase, showing that compound 16a significantly reduced rat prostate weight more than epristeride and exhibited excellent in vitro inhibitory potency, indicating its potential as a lead candidate for further benign prostatic hyperplasia drug research.
March 2016 in “European Urology Supplements” This study identified that methylation of the 5-AR2 gene promoter is linked to reduced expression of 5-AR2 protein, which may explain why some BPH patients are resistant to finasteride treatment.
January 2014 in “프로그램북(구 초록집)” This article reviews updates on 5 alpha-reductase inhibitors for treating male pattern hair loss and presents no new clinical findings; the author aims to enhance understanding of these therapies.